About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ADMS - Adamas Pharmaceutica...| Previous Close | $5.54 | Open | |
| Volume | 556 | Market Cap | 126.93M |
| Yield | Last Dividend |
| Adamas to Present at Upcoming ICR Confer... | 01/07/21 |
| EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering??? | |
| Adamas to Present at Upcoming H.C. Wainw... | 01/04/21 |
| EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering??? | |
| Adamas Announces New Employment Induceme... | 12/11/20 |
| EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of t... | |
| Adamas announces changes to its Board of... | 11/23/20 |
| EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering??? | |
| Adamas announces settlement agreement of... | 11/02/20 |
| EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering??? | |
| Adamas Pharmaceuticals (NASDAQ:ADMS) Rai... | 10/22/20 |
| Zacks Investment Research upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a sell rating to a hold rating in a research report released on... | |
| Adamas Pharmaceuticals (NASDAQ:ADMS) Upg... | 10/21/20 |
| Zacks Investment Research upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a sell rating to a hold rating in a research note released on M... | |
| Brokerages Set Adamas Pharmaceuticals In... | 10/21/20 |
| Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have been assigned a consensus rating of ???Buy??? from the nine research firms that are presently ... | |
| Zacks Investment Research Upgrades Adama... | 10/21/20 |
| Adamas Pharmaceuticals (NASDAQ:ADMS) was upgraded by Zacks Investment Research from a ???sell??? rating to a ???hold??? rating in a research note issu... | |
| Adamas Pharmaceuticals (NASDAQ:ADMS) Sha... | 10/20/20 |
| Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) fell 8.7% on Tuesday . The stock traded as low as $3.82 and last traded at $3.90. 510,174 shares tr... | |
| The Daily Biotech Pulse: Adamas Rallies ... | 06/05/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Bioh... | |
| All You Need to Know About Adamas (ADMS)... | 04/28/20 |
| Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| The Daily Biotech Pulse: NY State Endors... | 03/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10)... | |
| The Daily Biotech Pulse: Mesoblast To Te... | 03/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) A... | |
| Adamas Pharma EPS misses by $0.02, beats... | 02/25/20 |
| Adamas Pharma (NASDAQ:ADMS): Q4 GAAP EPS of -$0.83 misses by $0.02. Revenue of $16.35M (+22.7% Y/Y) beats by $0.09M. Shares +1.7%. Press Release | |
| ALERT: ROSEN, NATIONAL INVESTOR COUNSEL,... | 02/05/20 |
| NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceutica... | |
| ADMS INVESTOR DEADLINE IN 7 DAYS: Bernst... | 02/03/20 |
| NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plain... | |
| GE T&D bags Rs 173 cr JKPDD contract | 01/23/20 |
| GE T&D India on Thursday said it bagged a Supervisory Control and Data Acquisition (SCADA) and Advanced Distribution Management Solution (ADMS) projec... | |
| ADMS ROSEN, A TOP LAW FIRM, Reminds Adam... | 01/04/20 |
| NEW YORK, Jan. 04, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. bet... | |
| Glancy Prongay & Murray Reminds Investor... | 12/20/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharm... | |
| INVESTIGATION ALERT: The Schall Law Firm... | 12/17/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS #ADMS--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuti... | |
| Adamas drug to help MS patients walk doe... | 12/17/19 |
| REUTERS: Adamas Pharmaceuticals Inc said on Tuesday its drug to treat walking impairment in patients with multiple sclerosis did not show the ??? | |
| Is Adamas Pharmaceuticals Inc (ADMS) A G... | 12/16/19 |
| With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world pr... | |
| ADMS LOSS NOTICE ALERT: TOP RANKED Rosen... | 12/14/19 |
| NEW YORK, Dec. 14, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of... | |
| Adamas Pharmaceuticals : Glancy Prongay ... | 12/13/19 |
| Glancy Prongay & Murray LLP , a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that a... | |
| Glancy Prongay & Murray LLP Announces th... | 12/13/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Adamas Pharmaceutic... | |
| Shareholder Alert: Robbins LLP Announces... | 12/12/19 |
| SAN DIEGO & EMERYVILLE, Calif.--(BUSINESS WIRE)---- $ADMS #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Adamas P... | |
| Glancy Prongay & Murray LLP Announces In... | 12/12/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray LLP Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors | |
| Date | 2020-11-05 (AMC) | Est. (EPS/Rev.) | ($0.48)/ 20.95M |
| Actual (EPS/Rev.) | $-0.42/ $20.18 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
